RTRX Insider Trading Activity and SEC Form 4 Filings
RTRX insider trading summary
No open-market insider purchases or sales of Travere Therapeutics, Inc. (RTRX) have been reported on SEC Form 4 in the past 12 months.
Latest RTRX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 25, 2020 | Laura Clague | Chief Financial Officer | Sell | $85K (3,750 @ $22.72) |
| Nov 24, 2020 | Laura Clague | Chief Financial Officer | Sell | $89K (3,750 @ $23.86) |
| Nov 16, 2020 | Elizabeth E Reed | SVP, GC & Corporate Secretary | Sell | $60K (2,500 @ $23.98) |
| Nov 16, 2020 | William E. Rote | Senior Vice President, R&D | Sell | $60K (2,500 @ $23.96) |
| Nov 16, 2020 | Laura Clague | Chief Financial Officer | Sell | $180K (7,500 @ $23.98) |
| Nov 13, 2020 | Elizabeth E Reed | SVP, GC & Corporate Secretary | Sell | $59K (2,500 @ $23.62) |
| Nov 13, 2020 | William E. Rote | Senior Vice President, R&D | Sell | $59K (2,500 @ $23.62) |
| Nov 13, 2020 | Laura Clague | Chief Financial Officer | Sell | $177K (7,500 @ $23.61) |
| Nov 6, 2020 | Steve Aselage | Director | Sell | $474K (20,625 @ $23.00) |
| Nov 5, 2020 | Steve Aselage | Director | Sell | $53K (2,500 @ $21.26) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.